RCM Technologies, Inc. — Form 10-Q Summary
Period clarification: The request identifies 2021 Q3, but the supplied filing covers the 13 and 39 weeks ended October 1, 2022, compared with periods ended October 2, 2021. Amounts below are in U.S. dollars; financial figures are shown in millions unless noted.
Business context and reporting period
RCM provides engineering, specialty healthcare staffing and services, and life sciences and information technology services. This unaudited quarterly report covers the third quarter and first 39 weeks of fiscal 2022. Results reflect strong growth in Specialty Health Care and Engineering; the company cautions that interim results are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | 13 weeks ended Oct. 1, 2022 | 13 weeks ended Oct. 2, 2021 | 39 weeks ended Oct. 1, 2022 | 39 weeks ended Oct. 2, 2021 |
|---|---|---|---|---|
| Revenue | $58.2 | $45.5 | $214.5 | $139.0 |
| Gross profit / margin | $17.4 / 29.9% | $12.2 / 27.0% | $62.5 / 29.1% | $35.3 / 25.4% |
| Operating income / margin | $4.8 / 8.3% | $3.7 / 8.3% | $22.0 / 10.3% | $7.0 / 5.1% |
| Net income | $3.5 | $2.8 | $16.1 | $5.0 |
| Diluted earnings per share | $0.33 | $0.24 | $1.52 | $0.43 |
- Third-quarter revenue rose 27.9%; 39-week revenue rose 54.3%. Specialty Health Care generated $28.0 million in the quarter and $123.6 million year to date; 39-week segment revenue nearly doubled year over year.
- Gross margin improved year over year, helped by segment mix and execution. For the quarter, Engineering and Specialty Health Care margins were 25.5% and 32.1%, respectively; Life Sciences and IT margin was 33.0%.
- Operating cash flow was $20.9 million for the 39 weeks, versus $4.9 million a year earlier. Capital expenditures were $0.7 million. Cash increased to $0.8 million from $0.2 million at fiscal-year start.
- At October 1, current assets were $55.6 million and current liabilities $36.6 million, a $19.0 million working-capital surplus. Revolver borrowings were $1.2 million, down from $14.2 million at January 1; additional borrowing availability was $41.9 million. The company reported compliance with facility covenants.
- Financing cash outflow was $19.5 million, including $13.0 million of net revolver repayments and $6.4 million of share repurchases. A new repurchase authorization permits up to $25.0 million; $21.4 million remained available at quarter-end.
Material changes versus the prior comparable period
- Specialty Health Care growth reflected reopened school clients and high demand for healthcare professionals. School-client revenue for the 39 weeks rose to $90.4 million from $39.2 million.
- Engineering revenue increased on aerospace, industrial processing, and energy-services activity. Management cited a new aerospace outsourcing engagement, entry into the rocket industry, and customer investment in ethanol production upgrades.
- Life Sciences and IT revenue was nearly flat in the quarter but increased 6.4% for the 39 weeks; management attributed margin improvement to Life Sciences and managed-service offerings.
- Year-to-date operating income benefited from higher revenue and margins, but comparison is affected by a $2.2 million gain on the sale of Canadian Power Systems assets in the prior-year period; the current period recorded a $0.2 million gain.
Outlook, commentary, risks, and unusual items
- No specific revenue or earnings guidance was provided. Management said it believes liquidity is sufficient for at least the next 12 months and expects to remain covenant-compliant.
- Management described healthcare staffing demand as strong but noted difficulty recruiting nurses and other professionals. A shift in pandemic conditions, renewed virtual schooling, or reduced demand as COVID-19 becomes endemic could affect Specialty Health Care.
- Two customers each represented more than 10% of 39-week consolidated revenue, at 16.1% and 12.3%; both were in Specialty Health Care. Customer concentration, collections, hiring and retention, wage pressure, competition, economic cyclicality, and foreign-exchange movements are disclosed risks.
- The company had accrued $3.1 million for asserted claims. For an Industrial Processing customer claim concerning system performance, RCM reserved $0.5 million; it believes contractual damages may be capped at $3.3 million and insurance may apply, but gives no assurance on either limit or coverage.
- Effective October 2, 2022, RCM acquired TalentHerder’s fixed and intangible assets for $4.2 million cash and $0.6 million in restricted stock, with up to $11.3 million of additional contingent payments tied to operating income.
- The revolving facility bears variable interest; the reported weighted-average rate, including unused fees, was 2.7% for the 39 weeks. Management estimated a 1 percentage-point rate increase would raise annualized interest expense by about $0.1 million.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. It also disclosed a planned accounting-system upgrade estimated to cost $0.5–$1.0 million.
Important facts for investors to verify
- Whether healthcare staffing demand, professional availability, and school-client activity remain strong, and how much recent growth is sustainable.
- The extent of revenue and receivable exposure to the two large Specialty Health Care customers, including collection performance.
- Resolution, insurance coverage, and potential exposure relating to the Industrial Processing claim and other accrued legal matters.
- TalentHerder integration, performance against earn-out conditions, and potential contingent payments of up to $11.3 million.
- Use of the remaining repurchase authorization alongside working-capital needs, low cash balances, and revolver capacity.
- Confirm the intended reporting year: the supplied filing is for Q3 2022, not Q3 2021.